|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 5/14/21 Syneos Health, Inc. 8-K:5 5/12/21 10:171K ActiveDisclosure/FA |
Document/Exhibit Description Pages Size 1: 8-K Current Report HTML 35K 6: R1 Document and Entity Information HTML 46K 8: XML IDEA XML File -- Filing Summary XML 11K 5: XML XBRL Instance -- synh-8k_20210512_htm XML 14K 7: EXCEL IDEA Workbook of Financial Reports XLSX 6K 3: EX-101.LAB XBRL Labels -- synh-20210512_lab XML 56K 4: EX-101.PRE XBRL Presentations -- synh-20210512_pre XML 34K 2: EX-101.SCH XBRL Schema -- synh-20210512 XSD 18K 9: JSON XBRL Instance as JSON Data -- MetaLinks 12± 19K 10: ZIP XBRL Zipped Folder -- 0001564590-21-028058-xbrl Zip 10K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM i 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): i May 12, 2021
i SYNEOS HEALTH, INC.
(Exact name of registrant as specified in its charter)
|
i Delaware |
i 27-3403111 |
|
|
(State or other jurisdiction |
(Commission |
(IRS Employer |
|
i 1030 Sync Street i Morrisville, i North Carolina |
i 27560-5468 |
|
(Address of principal executive offices) |
(Zip Code) |
Registrant’s telephone number, including area code: ( i 919) i 876-9300
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
i ☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
i ☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
i ☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
i ☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
| i Class A Common Stock, |
|
i SYNH |
|
i The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company i ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section
13(a) of the Exchange Act. ☐
Item 5.07 Submission of Matters to a Vote of Security Holders.
On May 12, 2021, Syneos Health, Inc. (the “Company”) held its Annual Meeting of Stockholders. A total of 98,638,612 shares of the Company’s Class A common stock (“common stock”) were present online or represented by proxy at the meeting, representing approximately 94.64% of the Company’s outstanding common stock as of the March 19, 2021 record date. The following are the voting results for the proposals considered and voted upon at the meeting, each of which were described in the Company’s Definitive Proxy Statement filed with the Securities and Exchange Commission on March 31, 2021.
Proposal 1. Election of three directors for a term expiring at the 2024 annual meeting of stockholders and until their successors have been elected and qualified.
|
Nominee |
|
For |
|
Against |
|
Abstain |
|
Broker Non-Votes |
|
Thomas Allen |
|
82,653,679 |
|
12,730,118 |
|
576,209 |
|
2,678,606 |
|
Linda A. Harty |
|
95,352,400 |
|
454,719 |
|
152,887 |
|
2,678,606 |
|
Alistair Macdonald |
|
95,523,403 |
|
286,385 |
|
150,218 |
|
2,678,606 |
Proposal 2. Approval, on an advisory (nonbinding) basis, of the Company’s executive compensation.
|
For |
|
Against |
|
Abstain |
|
Broker Non-Votes |
|
94,109,560 |
|
1,689,915 |
|
160,531 |
|
2,678,606 |
Proposal 3. Ratification of the appointment of Deloitte & Touche LLP as the Company’s independent auditors for the year ending December 31, 2021.
|
For |
|
Against |
|
Abstain |
|
Broker Non-Votes |
|
98,394,924 |
|
64,490 |
|
179,198 |
|
0 |
Based on the foregoing votes, the three director nominees named above were elected and Proposals 2 and 3 were approved.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
SYNEOS HEALTH, INC. |
|
|
|
|
|
|
|
|
Date: |
By: |
/s/ Jonathan Olefson |
||
|
|
|
|
Name: |
|
|
|
|
|
Title: |
General Counsel and Corporate Secretary |
| This ‘8-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| 12/31/21 | 10-K | |||
| Filed on: | 5/14/21 | 4, 4/A | ||
| For Period end: | 5/12/21 | 4, DEF 14A | ||
| 3/31/21 | 10-Q, 4, DEF 14A, DEFA14A | |||
| 3/19/21 | ||||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 6/04/21 Syneos Health, Inc. 424B7 1:390K Donnelley … Solutions/FA |